Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Toolkit Designed to Expand Resources for Genomic Research

By BiotechDaily International staff writers
Posted on 28 Aug 2013
Image: The PhenX toolkit homepage. Use of PhenX toolkit measures helps researchers understand the relationships between genetics, health, disease, and environment (Photo courtesy of PhenX Toolkit, RTI).
Image: The PhenX toolkit homepage. Use of PhenX toolkit measures helps researchers understand the relationships between genetics, health, disease, and environment (Photo courtesy of PhenX Toolkit, RTI).
Use of a new genotype/phenotype resource should help researchers better determine the links between genetics, disease, health, and the environment.

As part of a new award from the US National Human Genome Research Institute (Bethesda, MD, USA), RTI International (Research Triangle Park, NC, USA) will expand the PhenX Toolkit, a web-based resource that supports collaborative genomics and biomedical research.

The goals of the four-year, USD 5.3 million award, the genomic resource grant for PhenX Toolkit include updating and expanding the Toolkit, integrating Chinese and Spanish translations of PhenX protocols and mapping PhenX variables to all completed studies in the database of genotypes and phenotypes (dbGaP).

“This award gives the PhenX team the opportunity to address the evolving needs of the scientific community by enhancing the content and features of the Toolkit,” said Carol M. Hamilton, PhD, director of bioinformatics at RTI and PhenX lead investigator. “The use of PhenX measures increases the opportunities for researchers to combine or compare their findings, thus increasing the impact of each individual study.”

The PhenX Toolkit, a web-based catalog of 339 well-established measures of phenotypes and exposures, combines data from a range of research and allows investigators to enlarge a study design beyond the basic research focus. Enhancements to PhenX measurements will increase the overall impact of individual studies by making it easier to compare and combine data.

“The PhenX Toolkit is a great resource for investigators who would like to strategically expand their study design by adding a few standard measures,” Dr. Hamilton said. “Because common, complex diseases share many risk factors, identification of these factors increases with the use of common measures in research studies.”

PhenX is driven by the scientific community and decisions are reached using an established consensus process. Since 2007, the RTI-led PhenX project has engaged working groups of experts to select high-priority measures and a steering committee to provide guidance and policymaking decisions.

The PhenX Toolkit currently has more than 1,100 registered users and is publically available at no cost online (please see Related Links below).

Related Links:

RTI International
PhenX Toolkit



view channel
Image: A new catalyst that improved the sensitivity of the standard PSA ELISA test by about 110-fold was made of palladium nanocubes coated with iridium (Photo courtesy of Dr. Xiaohu Xia, Michigan Technological University).

Peroxidase Mimic Outperforms Natural Horseradish Peroxidase in ELISA Test

A test-of-concept study demonstrated that a synthetic catalyst that mimics the action of horseradish peroxidase (HRP) could increase the sensitivity of a colorimetric enzyme-linked immunosorbent assay... Read more

Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more


view channel

Biopharmaceutical Partners Seek Alternatives to Glucocorticoid Steroid Drugs

Collaboration between American and Japanese biopharmaceutical companies is expected to lead to the development of a new class of small molecule drugs for treatment of hematological and inflammatory diseases. Gencia LLC (Charlottesville, VA, USA) and Takeda Pharmaceutical Company Ltd. (Osaka, Japan) announced the formation... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.